Kim Joong-Yub, Choi Yunhee, Yim Jae-Joon, Kwak Nakwon
Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA.
Open Forum Infect Dis. 2025 Mar 7;12(3):ofaf138. doi: 10.1093/ofid/ofaf138. eCollection 2025 Mar.
In a cohort of 534 patients treated for complex pulmonary disease, those who failed to achieve culture conversion were older, had higher proportions of males and cavity presence, were more likely to receive clofazimine and aminoglycosides, but less likely to receive rifampicin, and had a shorter overall treatment duration. Time-varying analysis of individual drug effects on time to culture conversion identified rifampicin as being associated with a reduced culture conversion rate (adjusted hazard ratio, 0.959; 95% confidence interval, .924-.995; = .027), suggesting a potentially negative effect on complex pulmonary disease outcomes, whereas other drugs showed no significant association.
在一组534例接受复杂性肺部疾病治疗的患者中，未实现培养转阴的患者年龄较大，男性比例和有空洞的比例较高，更有可能接受氯法齐明和氨基糖苷类药物，但接受利福平的可能性较小，且总体治疗时间较短。对个体药物对培养转阴时间的影响进行的时变分析确定，利福平与培养转阴率降低相关（调整后的风险比为0.959；95%置信区间为0.924 - 0.995；P = 0.027），这表明对复杂性肺部疾病的治疗结果可能有负面影响，而其他药物未显示出显著相关性。
